Key takeaways
- Kisspeptin is a family of hormones cut from one precursor protein made by the KISS1 gene: kisspeptin-54, -14, -13 and -10, named for their number of amino acids.
- They act on KISS1R (GPR54); genetic studies in 2003, of families with inherited hypogonadotropic hypogonadism (impaired puberty) and of mice bred without the receptor, placed it in the reproductive axis.
- In people, FDA found that most kisspeptin-10 studies examined its effects on GnRH and LH, and found no published trial that assessed its safety when given for more than one day (2024).
- FDA lists kisspeptin-10 in category 2 for compounding, and its advisory committee voted 0 to 11 in October 2024 against adding it to the 503A bulks list.
- WADA’s 2026 and 2027 Lists name “kisspeptin and its agonist analogues” in an entry for males, in a class prohibited at all times.
01Kisspeptin at a glance
The short version, dated 18 November 2026.
| Question | Kisspeptin |
|---|---|
| What it is | A hormone made from the KISS1 gene. One precursor protein is cut into kisspeptin-54, -14, -13 and -10. |
| Kisspeptin-10 | The shortest form: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, C63H83N17O14, 1302 g/mol. The longer forms end in the same ten amino acids. Also called metastin 45–54. |
| Receptor | KISS1R, also called GPR54: a G-protein-coupled receptor found in the hypothalamus, pituitary, placenta and pancreas of humans and rodents. |
| Role | An upstream regulator of GnRH secretion in the reproductive axis (FDA, 2024). |
| Evidence tier | T2: human genetics and small physiological and diagnostic studies. T3: animal studies. T4: cell studies. |
| United States | Not a component of any FDA-approved drug. Kisspeptin-10 has been in compounding category 2 (503A) since 29 Sep 2023. Advisory committee vote, 29 Oct 2024: 0 yes, 11 no. |
| Approved anywhere? | FDA, July 2024: “no approved product in any country containing kisspeptin-10”. The EMA’s data lists no kisspeptin medicine (17 Nov 2026). |
| Australia | Not named in the Poisons Standard October 2026, and not being named does not make it approved or permitted. We did not assess its group entries. |
| WADA | Named on the 2026 and 2027 Lists (S2.2.1, “kisspeptin and its agonist analogues”, for males), prohibited at all times. |
02What is kisspeptin?
Kisspeptin is a hormone the body makes. According to FDA’s 2024 review, the KISS1 gene encodes a precursor protein of 145 amino acids, which is cut into several active forms: kisspeptin-54, -14, -13 and -10, each named for its number of amino acids. All share the same ten amino acids at one end, the sequence of kisspeptin-10 itself.
The gene was found in cancer research. In 1996, researchers working with human melanoma cells whose ability to spread had been suppressed identified a gene they named KiSS-1. Its RNA appeared in non-spreading melanoma cells, and among normal tissues it was highest in the placenta (cell and tissue study, T4). FDA’s review dates the first literature on kisspeptin itself to 2001, in an article on kisspeptin-54 and its shorter forms.
The kisspeptin-10 used in research is synthetic. FDA describes it as “a synthetic non-glycosylated oligopeptide containing 10 amino acids”. How peptides like this are built: how peptides work.
03What does kisspeptin do in the reproductive axis, by model?
The reproductive axis runs from the brain to the pituitary to the testes or ovaries. FDA’s review places kisspeptin at the top: it is “an upstream regulator of GnRH secretion”, and activating its receptor increases the pituitary’s release of LH and FSH, the hormones that act on the testes and ovaries. Each model below shows a different part of that picture.
| Model | Study | What was found |
|---|---|---|
| Human genetics (T2) | de Roux et al., 2003: one large family in which five siblings had isolated hypogonadotropic hypogonadism, a shortfall of the pituitary hormones LH and FSH that impairs puberty and reproductive function | All five carried two copies of the same deletion in the GPR54 gene; unaffected relatives carried one copy or none |
| Human genetics and mice (T2, T3) | Seminara et al., 2003: a family whose affected members lacked pubertal development, one unrelated patient, and mice bred without the receptor | The affected people carried GPR54 mutations; the mice had isolated hypogonadotropic hypogonadism |
| Monkeys (T3) | Studies summarised by FDA (2024): continuous infusion of kisspeptin-10 in male rhesus monkeys | LH rose, then fell back to baseline after about 3 hours although the infusion continued, a loss of response called tachyphylaxis |
The genetic studies observe people born with a faulty receptor; they are not tests of giving kisspeptin. Their authors concluded that loss of GPR54 function is a cause of the condition.
04How has kisspeptin been studied in people?
Mostly in short studies in clinical research settings, to probe how the reproductive axis works or to test it.
FDA’s 2024 review found that most studies of kisspeptin-10 examined its effects on GnRH and LH, and that kisspeptin has been used “as a probe of GnRH neuronal function”. It counted about 300 people given kisspeptin-10 across small studies, a figure it said may overcount, and the longest exposure it found was 24 hours. Kisspeptin-54 has also been given in human studies. Two examples, described by design:
Physiology, 2005 (T2, n=6). A hospital-based, placebo-controlled crossover study gave 6 male volunteers kisspeptin-54 and saline on separate occasions, in random order, and measured LH, FSH and testosterone in their blood.
Diagnosis, 2020 (T2, n=16). A cohort study at an academic medical centre gave kisspeptin and GnRH stimulation tests to 16 children (3 girls, 13 boys) with delayed or stalled puberty, then followed them every 6 months to see whether their responses matched who later went through puberty.
Neither is a trial of kisspeptin as a treatment. FDA judged the evidence insufficient “to make a conclusion on the effectiveness of kisspeptin-10” for men with secondary hypogonadism. How we grade studies: evidence grades.
05What have regulators said about kisspeptin?
FDA, compounding list. FDA places bulk substances that “may present significant safety risks” in category 2, and kisspeptin-10 has been there, for 503A pharmacies, since 29 September 2023. Its entry reads: “Compounded drugs containing Kisspeptin-10 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has no, or only limited, safety-related information for the proposed routes of administration.” What the categories mean: FDA peptide categories.
FDA review, July 2024. In the small human studies it found, “No serious adverse events were reported”, but the studies “were of short duration, had small sample sizes, and often did not include information on adverse events”, and it found no published trial assessing safety beyond one day. For the routes proposed in the nomination, kisspeptin-10 “may pose a significant risk for immunogenicity”, and it found no study that had formally investigated this. In mice prone to atherosclerosis (T3), kisspeptin-10 sped the build-up of plaque in the aorta; FDA called this “concerning” and said its clinical relevance “remains unclear”. FDA’s adverse-event database held one report (searched to 25 October 2023), describing weight gain and a rise in the hormone estrone; FDA said the report was limited by “an unclear temporal relationship and insufficient information”.
FDA advisory committee, 29 October 2024. Asked whether kisspeptin-10 should go on the 503A bulks list, for the use FDA evaluated (secondary hypogonadism in men), the Pharmacy Compounding Advisory Committee voted 0 yes and 11 no, “due to the lack of convincing safety and efficacy data”, according to its final minutes.
Approval. FDA wrote in 2024 that there was “no approved product in any country containing kisspeptin-10”. On 18 November 2026, neither Drugs@FDA nor the EMA’s data on centrally authorised medicines listed a medicine containing any form of kisspeptin.
Sport. WADA’s 2026 and 2027 Prohibited Lists name “kisspeptin and its agonist analogues” in section S2.2.1, an entry for males, in class S2, prohibited at all times. See peptides and anti-doping.
06What we don’t know
- The effects of repeated exposure over weeks or months. FDA found no published trial assessing the safety of kisspeptin-10 given for more than one day.
- Whether the atherosclerosis finding in mice applies to people. FDA said its clinical relevance remains unclear.
- Whether kisspeptin-10 provokes immune reactions. FDA found no study that formally investigated it.
- What a product labelled kisspeptin-10 contains. FDA judged the nominated substance not well characterised, because data on its likely impurities were neither in the literature nor in the nominator’s certificate of analysis.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.